SK+F
Company type | Private Limited |
---|---|
Industry | Pharmaceutical Industry |
Founded | 1990 |
Founder | Latifur Rahman |
Headquarters | Plot: 82, Road: 14 Block - B, Banani, , Bangladesh |
Key people | Simeen Rahman (Managing Director & CEO) |
Revenue | US$300 million |
Parent | Transcom Group |
Website | skfbd |
Eskayef Pharmaceuticals Ltd., also known as SK+F, is a pharmaceutical company in Bangladesh. It belongs to the Transcom Group.[1][2] Simeen Rahman is the Managing Director and CEO of the company.[2][3]
History
[edit]Eskayef Bangladesh Ltd., a successor of Smith, Kline & French in Bangladesh, was acquired by Transcom in 1990.[2] According to an IMS report, the company was among the top six pharmaceutical companies operating in Bangladesh in terms of sales in 2021.[4] By 2021, it exported finished products to 65 countries.[2] The company was renamed Eskayef Pharmaceuticals Limited in January 2017.[5]
Products
[edit]The company is engaged in the manufacture and marketing of a wide range of therapeutic drugs, bulk pellets and animal health and nutrition products[6] including the oral anti covid medication Molnupiravir[7] & Nirmatrelvir co-packaged with Ritonavir and injectable Remdesivir.
References
[edit]- ^ Iqbal, Farah K. (2016-09-19). "What makes the market tick?". Dhaka Tribune (Op-ed). Retrieved 2016-10-03.
- ^ a b c d "Eskayef sales jump manifold". The Daily Star. 2015-12-29. Retrieved 2016-10-03.
- ^ "'I am the brand'". Prothom Alo. Archived from the original on 2016-09-24. Retrieved 2016-10-03.
- ^ Akter, Sayeda (2009-08-23). "Pharma industry set for expansion". The Daily Star. Retrieved 2016-10-03.
- ^ "Eskayef pledges to conquer odds with courage". The Daily Star. 2017-01-24.
- ^ "Eskayef beats rivals in sales growth". The Daily Star. 2012-01-26.
- ^ "Beximco, Eskayef to produce Covid drug". businesspostbd.com. Retrieved 2021-11-10.
Further reading
[edit]- Rahman, Md Fazlur (2015-03-24). "Novo Nordisk: Ethically profitable". The Daily Star. Retrieved 2016-10-03.
External links
[edit]